NCT00049192View on ClinicalTrials.gov

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

November 30, 2005

Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
Interventions
BIOLOGICAL

oblimersen sodium

Given IV

DRUG

imatinib mesylate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00049192 - Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter